When and how to treat essential thrombocythemia

N Engl J Med. 2005 Jul 7;353(1):85-6. doi: 10.1056/NEJMe058093.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Aspirin / therapeutic use
  • Drug Therapy, Combination
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control
  • Humans
  • Hydroxyurea / adverse effects
  • Hydroxyurea / therapeutic use*
  • Leukemia, Myeloid, Acute / etiology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Primary Myelofibrosis / etiology
  • Quinazolines / therapeutic use*
  • Risk Factors
  • Thrombocythemia, Essential / complications
  • Thrombocythemia, Essential / drug therapy*
  • Thrombosis / etiology
  • Thrombosis / prevention & control

Substances

  • Antineoplastic Agents
  • Platelet Aggregation Inhibitors
  • Quinazolines
  • anagrelide
  • Aspirin
  • Hydroxyurea